| Patents for A61P 21 - Drugs for disorders of the muscular or neuromuscular system (23,287) |
|---|
| 04/18/2002 | US20020045641 Multiple heteroatom containing heterocyclic ring compounds substituted with carboxylic acids and isosteres thereof |
| 04/18/2002 | US20020045635 Novel mGluR antagonists and a method for their synthesis |
| 04/18/2002 | US20020045623 Stable; potent; penetrates cell membranes; effectively hinders cellular apoptosis; Antiinflammatory agents, Ischemic agents, cancer, autoimmune diseases and nervous system disorders. |
| 04/18/2002 | US20020045615 Benzothiazole derivatives with activity as adenosine receptor ligands |
| 04/18/2002 | US20020045613 1-aroyl-piperidinyl benzamidines |
| 04/18/2002 | US20020045264 Expression vectors for use in gene therapy |
| 04/18/2002 | US20020045229 Nucleotide sequences coding membrane protein for use inthe treatment of epilepsey, arrhythmia, and pain in humans |
| 04/18/2002 | US20020044924 Extracorporeal treatment of the patient's blood cells to induce apoptosis and administration of the apoptotic bodies and/or cells to patient; T-cell- mediated and inflammatory disorders |
| 04/18/2002 | CA2425593A1 Uridine therapy for patients with elevated purine levels |
| 04/18/2002 | CA2425508A1 Targeted therapeutic agents |
| 04/18/2002 | CA2425001A1 Novel serine protease genes related to dppiv |
| 04/18/2002 | CA2424992A1 Paramyxovirus vectors for introducing foreign genes into skeletal muscle |
| 04/18/2002 | CA2424983A1 Nucleic acid molecules and polypeptides for immune modulation |
| 04/18/2002 | CA2424292A1 Tricyclic compounds and uses thereof |
| 04/18/2002 | CA2424107A1 Sulfonylguanidines |
| 04/17/2002 | EP1197209A1 Percutaneously absorbable preparations |
| 04/17/2002 | EP1196598A1 Dsp-3 dual-specificity phosphatase |
| 04/17/2002 | EP1196577A2 Cell cycle and proliferation proteins |
| 04/17/2002 | EP1196574A2 Human proteins involved in detoxification |
| 04/17/2002 | EP1196569A2 Electron transfer proteins |
| 04/17/2002 | EP1196568A1 Human lim domain proteins |
| 04/17/2002 | EP1196567A2 Human immune response molecules |
| 04/17/2002 | EP1196441A1 Keratinocyte growth factor-2 |
| 04/17/2002 | EP1196440A2 Therapeutic peptides derived from subsequences of bpi |
| 04/17/2002 | EP1196419A1 Potassium channel blocking agents |
| 04/17/2002 | EP1196404A1 Piperazine derivatives as modulators of chemokine receptor activity |
| 04/17/2002 | EP1196395A1 Cyclized amino acid derivatives |
| 04/17/2002 | EP1196391A1 Benzimidazolone derivatives and their use as phosphodiesterase inhibitors |
| 04/17/2002 | EP1196389A1 N-heterocyclic derivatives with neuronal activity |
| 04/17/2002 | EP1196387A1 Azo amino acid derivatives for the treatment of neurological diseases |
| 04/17/2002 | EP1196386A2 N-substituted glycine derivatives |
| 04/17/2002 | EP1196385A1 Beta-amino acid derivatives for the treatment of neurological diseases |
| 04/17/2002 | EP1196186A2 Promotion or inhibition of angiogenesis and cardiovascularization by tumor necrosis factor ligand/receptor homologs |
| 04/17/2002 | EP1196176A1 Use of beta-napthoquinone for making medicines having an inhibiting effect on the release of glutamate by the brain |
| 04/17/2002 | EP1196169A1 Compounds having cytokine inhibitory activity |
| 04/17/2002 | CN1345335A Melanocortin receptor ligands |
| 04/17/2002 | CN1345314A Amine derivatives as protease inhibitors |
| 04/16/2002 | US6372754 Drugs for treatment or prevention of depression, anxiety, pain, inflammation, migraine, emesis or postherpic neuralgia. |
| 04/16/2002 | US6372473 Tissue plasminogen activator-like protease |
| 04/16/2002 | US6372433 Antisense modulation of inhibitor of DNA binding-1 expression |
| 04/11/2002 | WO2002029088A2 Highly expressible genes |
| 04/11/2002 | WO2002029061A2 G-protein coupled receptors |
| 04/11/2002 | WO2002029058A2 Human proteins, polynucleotides encoding them and methods of using the same |
| 04/11/2002 | WO2002029055A2 Carbohydrate-associated proteins |
| 04/11/2002 | WO2002029038A2 Novel proteins and nucleic acids encoding same and antibodies directed against these proteins |
| 04/11/2002 | WO2002029036A2 Lipid metabolism enzymes |
| 04/11/2002 | WO2002028866A2 Hydroxyesters of 7-desmethylrapamycin |
| 04/11/2002 | WO2002028816A1 Substituted 5-amino-1-pentene-3-ol derivatives |
| 04/11/2002 | WO2002028433A2 Use of a ppar delta activator in the treatment of diseases related to no inhibit ion or tnf inhibition |
| 04/11/2002 | WO2002028425A2 Methods for treating muscle injuries |
| 04/11/2002 | WO2002028165A2 Compositions and methods of using capsid protein from flaviviruses and pestiviruses |
| 04/11/2002 | WO2002000725A3 G-protein coupled receptor org10 |
| 04/11/2002 | WO2001092308A3 Cystine-knot polypeptides: cloaked-2 molecules and uses thereof |
| 04/11/2002 | WO2001090070A3 Caspase inhibitors and uses thereof |
| 04/11/2002 | WO2001087342A3 Delivery devices for treatment of vascular disease |
| 04/11/2002 | WO2001024782A3 Pharmaceutical agent for the treatment of cachexia and/or cardiogenic shock |
| 04/11/2002 | WO2000052210A3 Methods for targeting rna molecules |
| 04/11/2002 | WO2000047762A9 Enriched central nervous system cell populations |
| 04/11/2002 | WO2000044334A3 Novel injectable muscle relaxant formulations |
| 04/11/2002 | US20020042535 Therapeutic compounds and methods of use |
| 04/11/2002 | US20020042442 Ureas and carbamates of N-Heterocyclic carboxylic acids and carboxylic acid isosteres |
| 04/11/2002 | US20020042415 Dipeptide derivatives |
| 04/11/2002 | US20020042376 Antiinflammatory agents; autoimmune disease; antiischemic agents |
| 04/11/2002 | DE10048714A1 5-Amino-1-penlen-3-ol-Derivate 5-amino-1-penlen-3-ol derivatives |
| 04/11/2002 | CA2425269A1 G-protein coupled receptors |
| 04/11/2002 | CA2425152A1 Highly expressible genes |
| 04/11/2002 | CA2425126A1 Lipid metabolism enzymes |
| 04/11/2002 | CA2424216A1 Compositions and methods of using capsid protein from flaviviruses and pestiviruses |
| 04/11/2002 | CA2424199A1 Novel human proteins, polynucleotides encoding them and methods of using the same |
| 04/11/2002 | CA2423929A1 Carbohydrate-associated proteins |
| 04/11/2002 | CA2423888A1 Hydroxyesters of 7-desmethylrapamycin |
| 04/11/2002 | CA2423677A1 Novel proteins and nucleic acids encoding same and antibodies directed against these proteins |
| 04/10/2002 | EP1194543A2 HUMAN PROTEINS HAVING HYDROPHOBIC DOMAINS AND DNAs ENCODING THESE PROTEINS |
| 04/10/2002 | EP1194448A1 Seven transmembrane receptor genes |
| 04/10/2002 | EP1194410A1 Benzimidazole derivatives and pharmaceutical compositions comprising these compounds |
| 04/10/2002 | EP1194409A1 Pyrazolidinol compounds |
| 04/10/2002 | EP1194172A1 Compositions and methods for the treatment or prevention of autoimmune disorders |
| 04/10/2002 | EP1194167A1 Immunotherapy of autoimmune disorders using antibodies which target b-cells |
| 04/10/2002 | EP1030845B1 Heterocyclic compounds having mmp and tnf inhibitory activity |
| 04/10/2002 | EP0950046B1 3,4-disubstituted azetidin-2-one derivatives useful as cysteine proteinase regulators |
| 04/10/2002 | EP0771191B1 Immunological activity of rhamnolipids |
| 04/10/2002 | CN1344160A Heterocyclic aromatic compounds useful as growth hormone secretagogues |
| 04/10/2002 | CN1344155A Transnasal transport/immunisation with highly adaptable carriers |
| 04/09/2002 | US6369222 mGluR antagonists and a method for their synthesis |
| 04/09/2002 | US6369201 For increasing muscle synthesis and treating disease in vertebrate subjects, for reducing myostatin activity |
| 04/09/2002 | US6369082 Carboxylic acids and acylsulfonamides, compositions containing such compounds and methods of treatment |
| 04/09/2002 | US6369047 Androgenic steroid compounds and a method of making and using the same |
| 04/09/2002 | US6368787 Methods and compositions for identifying morphogenic protein analogs using morphogenic protein responsive inhibitory elements |
| 04/09/2002 | CA2298572C Deuterated cyclosporine analogs and their use as immunomodulating agents |
| 04/04/2002 | WO2002026997A2 Dsp-16 dual-specificity phosphatase |
| 04/04/2002 | WO2002026977A1 Host cell obtained by transferring vhl gene into cancer cell or embryonic stem cell and expressing |
| 04/04/2002 | WO2002026825A2 G-protein coupled receptors |
| 04/04/2002 | WO2002026245A2 Use of serp-1 in combination with an immunosuppressant for influencing inflammatory and immune reactions |
| 04/04/2002 | WO2002026227A1 Lactone integrin antagonists |
| 04/04/2002 | WO2002026223A2 Catecholamine pharmaceutical compositions and methods |
| 04/04/2002 | WO2002014281A8 Pyridine derivatives as inhibitors of p38 |
| 04/04/2002 | WO2001089451A3 Protease inhibitors |
| 04/04/2002 | WO2001087376A8 Drug/drug delivery systems for the prevention and treatment of vascular disease |
| 04/04/2002 | WO2001087263A3 Delivery systems for treatment of vascular disease |
| 04/04/2002 | WO2001085980A3 Enzymatic assays for screening anti-cancer agents |